Table 3.

Association between variables and pain trajectories from a multivariable multinomial logistic regression using 50 multiple imputed datasets (n=851)

Variable	Relative risk ratio (95% CI)
	Improved versus Consistently low	Consistently high versus consistently low	Consistently high versus improved
Baseline
Gender (base: female)
Male	0.5 (0.3 to 0.9)*	0.7 (0.4 to 1.4)	1.5 (0.9 to 2.5)
Age at onset, per year	1.1 (0.99 to 1.1)	1.1 (1.1 to 1.2)*	1.1 (1.0 to 1.2)*
PGA, per cm	1.1 (0.9 to 1.3)	1.1 (0.9 to 1.3)	1.0 (0.8 to 1.2)
Disease duration, per month	1.02 (1.0 to 1.04)*	1.03 (1.0 to 1.1)*	1.0 (0.99 to 1.0)
AJC, per joint	0.9 (0.8 to 1.1)	0.95 (0.8 to 1.1)	1.0 (0.9 to 1.1)
PGE, per cm	1.3 (1.0 to 1.5)*	1.4 (1.1 to 1.7)*	1.1 (0.9 to 1.3)
CHAQ, per 0.125	1.1 (0.96 to 1.1)	1.2 (1.0 to 1.3)*	1.1 (1.0 to 1.2)*
Pain, per cm	3.2 (2.5 to 4.1)*	3.1 (2.4 to 4.0)*	1.0 (0.8 to 1.1)
MFQ, per 5%	1.3 (0.7 to 2.5)	1.3 (0.6 to 2.8)	1.0 (0.6 to 1.7)
Early change
DMARDs in 1st year (base: no)
Yes	1.2 (0.7 to 2.1)	0.8 (0.4 to 1.5)	0.6 (0.4 to 1.1)*
Biologics in 1st year (base: no)
Yes	2.3 (0.8 to 6.1)	3.0 (1.0 to 8.8)*	1.3 (0.7 to 2.6)
Steroids in 1st year (base: no)
Yes	1.0 (0.5 to 1.9)	1.4 (0.7 to 3.1)	1.4 (0.8 to 2.6)
Change in AJC in 1st 6 months, per joint increase	0.9 (0.8 to 1.1)	1.0 (0.8 to 1.1)	1.0 (0.9 to 1.1)
Change in PGA in 1st 6 months, per cm increase	1.2 (0.9 to 1.4)	1.1 (0.9 to 1.4)	1.0 (0.8 to 1.2)
Change in PGE in 1st 6 months, per cm increase	1.3 (1.1 to 1.5)*	1.4 (1.2 to 1.7)*	1.1 (1.0 to 1.3)*
Change in CHAQ in 1st year, per 0.125 increase	1.1 (1.01 to 1.2)*	1.2 (1.1 to 1.3)*	1.1 (1.0 to 1.1)*
Change pain in 1st year, per cm increase	1.4 (1.2 to 1.7)*	1.7 (1.4 to 2.1)*	1.2 (1.1 to 1.3)*

*P≤0.05.

CHAQ, Childhood Health Assessment Questionnaire; DMARDs, disease-modifying antirheumatic drugs; MFQ, Moods and Feelings Questionnaire; PGA, Physician’s Global Assessment; PGE, parent’s/patient’s general evaluation.